INTRODUCTION: In this study, it was aimed to measure TLQP-21 neuropeptide plasma levels, which is thought to be effective in preventing or treating obesity in morbidly obese and normal weight healthy individuals, and to make a comparison between both groups. METHODS: Fifty-one morbidly obese patients with a body mass index (BMI) of 40 kg/m2 and above and 22 healthy individuals of normal weight with a BMI between 18.5-24.9 kg/m2 without any metabolic disease were included in the study. Enzyme- linked immunosorbent analysis (ELISA) test was performed on plasma samples taken from all individuals participating in the study. All data were evaluated statistically. RESULTS: Although it was observed that TLQP-21 peptide values in morbidly obese individuals increased compared to healthy individuals with normal weight, this increase was not statistically significant (p>0.05) (p=0.718). The amount of TLQP-21 peptide was also evaluated according to gender distributions in the whole study group, but any statistically significant difference was not determined. DISCUSSION AND CONCLUSION: Our study showed that there is no difference in plasma levels of TLQP-21 neuropeptide, which is thought to play a key role in the treatment of obesity, in mordidly obese and healthy individuals.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.